Administration of Amino-glycoside in ICU Patients : Clinical Practices in 2013 (NCT02888470) | Clinical Trial Compass
CompletedNot Applicable
Administration of Amino-glycoside in ICU Patients : Clinical Practices in 2013
France90 participantsStarted 2013-06
Plain-language summary
The aim of the study is to estimate the proportion of intensive care unit patients receiving current aminoglycosides dosing regimens as part of their antibiotic therapy and achieving the recommended maximal plasma concentration (Cmax) after the first and subsequent aminoglycoside doses.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18 years
* indication of aminogycoside therapy for a current infectious episode
Exclusion Criteria:
* \<18years
* allergy to aminoglycosides
* patients under guardianship
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study looked at how well ICU patients with sepsis actually reached the recommended peak blood levels of aminoglycoside antibiotics — how does that finding apply to the way aminoglycosides might be dosed if I or my loved one needs them in the ICU?
2Since this was an observational study tracking real-world clinical practices rather than testing a new treatment, what did doctors learn from it about whether standard aminoglycoside dosing is reliable enough, and does that change how our hospital approaches it today?
3The study measured peak drug levels after both the first and later doses — does that mean the right dose is hard to get on the first try, and how would my care team monitor and adjust dosing if aminoglycosides are part of my sepsis treatment?
4Aminoglycosides can have serious side effects on the kidneys and hearing — given that this study was looking at whether patients even reached target levels, what does that tell us about the balance between getting an effective dose and avoiding toxicity?
5Are there alternative antibiotics for treating sepsis that my doctor might consider instead of aminoglycosides, especially if hitting the right blood level consistently is known to be challenging in ICU patients?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Achievement of the recommended Cmax after the first and subsequent aminoglycoside doses.